Comparison of the effectiveness of first- and second-line canakinumab therapy in pediatric colchicine-resistant familial Mediterranean fever: a real-world study

Background Comparative data on first-line versus second-line canakinumab following anakinra in pediatric colchicine-resistant familial Mediterranean fever (crFMF) are lacking. We compared effectiveness, flare characteristics, and flare-free survival between treatment sequences.Research design and methods This retrospective single-center cohort study included 89 pediatric patients with crFMF carrying biallelic pathogenic exon 10 Mediterranean Fever gene (MEFV) variants who received canakinumab for at least 6 months, either as first-line therapy (n = 48) or following anakinra (n = 41).Results Canakinumab significantly reduced median Pras Disease Severity Score from 8 to 6 and International Severity Scoring System for familial Mediterranean fever from 4 to 1 (both p < 0.001). Patients receiving first-line canakinumab had fewer attacks during the first 6 months (p = 0.014), lower early flare rates (2.1% vs 17.1%; p = 0.022), and a longer time to first flare (14 vs 10 months; p = 0.030) than those receiving second-line treatment. Flare-free survival tended to favor first-line treatment (35 vs 19 months; log-rank p = 0.087), while overall flare rates were similar. Most first flares occurred during dose-interval extension, particularly at 8 weeks.Conclusions Canakinumab provided effective disease control regardless of treatment sequence. However, patients receiving first-line canakinumab experienced fewer early flares and a longer time to first flare compared with those receiving second-line treatment.

Authors

Institutions

Publication Details

Journal
Expert Opinion on Biological Therapy
Published
2026-11-14
DOI
https://doi.org/10.1080/14712598.2026.2763307
Primary Topic
Inflammasome and immune disorders
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

Comparison of the effectiveness of first- and second-line canakinumab therapy in pediatric colchicine-resistant familial Mediterranean fever: a real-world study

Betül Sözeri, Sıla Atamyıldız Uçar, Eray Tunce, Neslihan Kara Çanlıoğlu
Expert Opinion on Biological Therapy
Inflammasome and immune disorders
article

Comparison of the effectiveness of first- and second-line canakinumab therapy in pediatric colchicine-resistant familial Mediterranean fever: a real-world study

Betül Sözeri, Sıla Atamyıldız Uçar, Eray Tunce, Neslihan Kara Çanlıoğlu
article en

Abstract

Background Comparative data on first-line versus second-line canakinumab following anakinra in pediatric colchicine-resistant familial Mediterranean fever (crFMF) are lacking. We compared effectiveness, flare characteristics, and flare-free survival between treatment sequences.Research design and methods This retrospective single-center cohort study included 89 pediatric patients with crFMF carrying biallelic pathogenic exon 10 Mediterranean Fever gene (MEFV) variants who received canakinumab for at least 6 months, either as first-line therapy (n = 48) or following anakinra (n = 41).Results Canakinumab significantly reduced median Pras Disease Severity Score from 8 to 6 and International Severity Scoring System for familial Mediterranean fever from 4 to 1 (both p < 0.001). Patients receiving first-line canakinumab had fewer attacks during the first 6 months (p = 0.014), lower early flare rates (2.1% vs 17.1%; p = 0.022), and a longer time to first flare (14 vs 10 months; p = 0.030) than those receiving second-line treatment. Flare-free survival tended to favor first-line treatment (35 vs 19 months; log-rank p = 0.087), while overall flare rates were similar. Most first flares occurred during dose-interval extension, particularly at 8 weeks.Conclusions Canakinumab provided effective disease control regardless of treatment sequence. However, patients receiving first-line canakinumab experienced fewer early flares and a longer time to first flare compared with those receiving second-line treatment.

Expert Opinion on Biological Therapy
Sağlık Bilimleri Üniversitesi (TR)
Inflammasome and immune disorders
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon